Race for new antibiotics intensifies as WHO warns drug pipeline remains thin, and remains structurally unfit to support antibiotic innovation ...

Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

Multidrug-resistant gram-negative infections (MDRGNIs) are an emerging and deadly threat worldwide. Some of these infections are now resistant to nearly all antibiotics, and very few treatment options ...

Please provide your email address to receive an email when new articles are posted on . Gram-negative bacteria comprise most of the CDC and WHO’s lists of critical and urgent antibiotic-resistant ...

Clinicians should remain vigilant when prescribing antibiotics for gram-negative urinary tract infections due to the evolving spectrum of antimicrobial resistance. Clinicians should consider the ...

Urinary tract infections (UTIs) are common, but increasingly hard to treat because the bacteria that cause them are developing resistance to many antibiotics. Researchers headed by a team at the ...

Please provide your email address to receive an email when new articles are posted on . Ninety-day risk of all-cause mortality was 11.2% and 9.9% for patients given a shorter or longer antibiotic ...

Scientists at Duke University report they have developed a synthetic antibiotic that could be effective against drug-resistant superbugs and bacteria such as Salmonella, Pseudomonas, and E. coli.

Since the 1960s, there has been a decline in the discovery of new antibiotics, particularly against Gram-negative bacteria. Increases in antibiotic resistance call for an urgent need to identify ...

Hospital uptake of newer antibiotics to treat multidrug-resistant gram-negative bacteria was low over a 5-year period, according to a retrospective cohort study. Fully 41.5% of episodes of ...